Fig. 7: YAP1 expression level correlates with poor survival and clinicopathological features in CCA patients. | Cell Death & Disease

Fig. 7: YAP1 expression level correlates with poor survival and clinicopathological features in CCA patients.

From: Regorafenib inhibits epithelial-mesenchymal transition and suppresses cholangiocarcinoma metastasis via YAP1-AREG axis

Fig. 7

A Heat map of YAP1 gene expression from the TCGA RNA sequencing database in noncancerous and tumor tissues derived from CCA patients. B YAP1 gene expression from the TCGA RNA sequencing database in unpaired noncancerous and tumor tissues derived from CCA patients. C YAP1 gene expression from the TCGA RNA sequencing database in paired noncancerous and tumor tissues derived from CCA patients. D Representative IHC staining intensity of YAP1 protein in CCA tissues. Scale bar: 50 µm. E Representative IHC staining for YAP1 protein expression in benign and malignant tissues derived from patients with CCA. Scale bar: 50 µm. F Kaplan–Meier plots of recurrence-free survival of 95 CCA patients underwent hepatectomy according to YAP1 expression. The significance of the difference was determined using the nonparametric Mann–Whitney U-test.

Back to article page